A phase 1 b clinical trial of the CD 40-activating antibody CP-870 , 893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma A. K. Nowak1,2,3*, A. M. Cook2,3, A. M. McDonnell2,3, M. J. Millward1,2, J. Creaney2,3, R. J. Francis2,3,4, A. Hasani1, A. Segal5, A. W. Musk2,6,7, B. A. Turlach8, M. J. McCoy2,9, B. W. S. Robinson2,3,6 & R. A. Lake2,3 Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth; School of Medicine and Pharmacology; National Research Centre for Asbestos Related Diseases, University of Western Australia, Perth; Department of Nuclear Medicine; PathWest and; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth; School of Population Health; Centre for Applied Statistics, University of Western Australia, Perth; St John of God Hospital, Perth, Australia